| CAT'S CLAW (VINCARIA)
Uncaria tomentosa (Willd.) DC.; Uncaria guianensis
(Aubl.) Gmel.
[Fam. Rubiaceae] OVERVIEW Cat’s claw, also known by its Spanish name, uña
de gato, is an herb that has gained recent popularity in the
U.S. herb market. Uña de gato is the common name for
at least 20 plants (from 12 different families) with sharp,
curved thorns (Obregon, 1995; Cabieses, 1994). Among them
are two climbing, woody vines: Uncaria tomentosa and U. guianensis,
the two species of Uncaria (there are approximately 60 species)
native to the South and Central American tropical rain forests
that are the subject of this monograph. According to U.S.
herb industry policy, the standardized common name “cat’s
claw” refers to only U. tomentosa (McGuffin et al.,
2000), presumably because products containing U. guianensis
were not generally available in the U.S. market during most
of the 1990s, having been introduced in the past several years.
[Editors’ note: For the purposes of this monograph,
U. tomentosa will be abbreviated as “UT” and U.
guianensis will be abbreviated as “UG”. Because
the information on each species and chemotype may be specific
to that particular species or chemotype, it may have been
preferable to write two or three separate monographs instead
of one. However, the editors chose to include all the relevant
information on “cat’s claw” in this single
monograph, with subheadings designating species and chemotypes,
where applicable. In doing so, the editors acknowledge that
actions and uses based on one species or chemotype may not
be transferable to another.]
Both UT and UG are said to have a long history of use by the
indigenous people to treat a diverse set of health problems,
particularly rheumatism, arthritis, and other chronic inflammatory
disorders, gastric ulcers and gastrointestinal disorders,
tumors, and as a contraceptive (Cabieses, 1994; Jones, 1995;
Obregon, 1995; Anon.,1996; Miller, 2001). Although no written
records are available describing their traditional use (Cabieses,
1994), a study of the medicinal system of the Ashaninca (also
spelled Asháninka) tribe in Peru has been published
[TK: ref]. To the priests of this tribe, cat’s claw
(UT) is a sacred plant used to eliminate disturbance in the
communication between body and spirit (Keplinger et al., 1999).
One account of the Asháninka Indians states that the
priests differentiate between the two UT chemotypes and use
only the pentacyclic oxindole alkaloid (POA) chemotype (Keplinger,
1999), but how the priests can distinguish between chemotypes
without the scientific tools of chemical analysis is not described.
Despite some recent interest in this herb’s potential
immunomodulating activity, ethnomedical evidence of such use
is lacking.
Several types of cat’s claw preparations have grown
in popularity in the U.S. with the market defined by the following
four types of products offered mainly by three manufacturers,
each with their own distinct focus: (1) a hydroalcoholic UT
extract standardized to pentacyclic oxindole alkaloids (POAs),
(2) an aqueous UT extract standardized to carboxy alkyl esters
(CAEs), (3) and an aqueous UG extract. A fourth type of relatively
generic cat’s claw product (usually labeled as UT) is
made from the raw root bark, either powdered in capsules and
tablets, or finely cut for tea products (decoction, the traditional
form of use). Little scientific research has been performed
on this fourth class of crude products. Occasionally, products
labeled as “cat’s claw” in ethnic markets
have been shown to be mislabeled due to the vast number of
plants going by the common name cat’s claw and the lack
of adequate quality control in some small importers and distributors.
in 199?TK a case of poisoning was reported in South Texas
involving a product labeled “cat’s claw”
containing…. [TK-MB: in HG database, MB searching.]
Fourteen clinical trials on various preparations are summarized
herein. One controlled clinical trial with UG suggests efficacy
in the treatment of osteoarthritis of the knee (Piscoya et
al., 2001). While cat’s claw’s popularity is partly
due to European reports of its clinical effectiveness in combination
with AZT (zidovudine) for AIDS treatment, these findings need
to be confirmed by well-controlled clinical studies. Other
current studies report on cat’s claw’s anti-inflammatory
and antioxidant properties, and its ability to affect gene
expression and thereby modulate the immune system.
Cat’s claw is not yet popular in mainstream retail markets,
being sold primarily in health food stores where it ranked
25th in total herb sales in 2000 (Richman and Witkowski, 2001),
mail order, and in the ethnic Hispanic market. DESCRIPTION Cat’s claw preparations are made from extracts of the
dried stalk or root bark of U. tomentosa (Willd.) DC. or U.
guianensis (Aubl.) Gmel. [Fam. Rubiaceae]. Given that a considerable
proportion of the cat’s claw is still wild harvested,
it would be prudent not to utilize the root, as the vine can
regenerate when the stalk is cut above ground level. Uncaria
tomentosa and U. guianensis are distinguished by flower color,
thorn shape, and leaf characteristics (Jones, 1995; Cabrieses,
1994). The U. tomentosa plants occur naturally as two chemotypes
that appear identical botanically, but are chemically different
in their alkaloid content (Laus et al., 1997). One chemotype contains predominantly pentacyclic oxindole
alkaloids (POAs) with little or no tetracyclic oxindole alkaloids,
and the other contains tetracyclic oxindole alkaloids (TOAs)
with either no POAs or up to a considerable amount. TOAs are
believed to act antagonistically to some POA activity (Wurm
et al., 1998). Studies demonstrating that purified POA or
TOA share the same bioactivity as cat’s claw preparations
but enhanced for the relative concentrations in these extracts
are lacking, and it may well be that these chemical constituents
are more useful as marker compounds rather than mediating
the bioactivity of the botanical While early studies focused
on POAs as the active components, more recent studies report
that activity is well spread over a range of polar materials.
Several commercial preparations of U. tomentosa are available:
one hydroalcoholic extract standardized to POAs (containing
no TOAs); a nonstandardized mixture of both chemotypes; and
an aqueous extract, ultrafiltrated, containing a negligible
level of oxindole alkaloids, and standardized to carboxy alkyl
esters (CAEs). One U. guianensis preparation is available
that is composed of a freeze-dried aqueous extract. No monographs
on any cat’s claw preparation have been published to
date in any official pharmacopeias. PRIMARY USES Anti-Inflammatory
** Osteoarthritis (of the knee)
• UG: reduces pain (Piscoya et al., 2001) ** Rheumatoid Arthritis, adjunct therapy to conventional
treatment
• UT-POAs: reduces number of painful and swollen joints
(Mur et al., 2002; Immodal, 1995, 2002) OTHER POTENTIAL USES [Editors’ note: the following other potential uses
are based on clinical trials unless otherwise noted.]
** Anti-inflammatory, Gastrointestinal
• UG: protects gastric epithelial cells against NSAID-induced
gastritis and apoptosis in in vitro tests (Sandoval et al.,
2002; Miller et al., 1999)
• UT-unspecified: protects gastric epithelial cells
against NSAID-induced gastritis and apoptosis in animal and
in vitro tests (Sandoval et al., 2002; Sandoval-Chacon et
al., 1998)
• UT-POAs: ulcers and gastritis (Immodal 1995, 1999a) ** Antioxidant
• UG: effectively scavenges DPPH (a, a-diphenyl-ß-picrylhydrazyl),
protects against deoxyribose degradation, and inhibits ABTS
(2,2’-azinobis[3-ethyl-benzthiazoline-6-sulfonic acid])
radicals in in vitro tests (Sandoval et al., 2002); limits
gastric epithelial cell death in response to oxidative stress
in vitro (Miller et al., 2001)
• UT-unspecified: effectively scavenges DPPH, protects
against deoxyribose degradation, and inhibits ABTS radicals
in in vitro tests (Sandoval et al., 2002); cytoprotective
against oxidative stress in vitro(Sandoval-Chacon et al.,
1998) ** Cancer, adjunctive to chemotherapy & radiation
• UT-POAs: increases vitality and reduces side effects
(Immodal, 1995, 1999a, 2002) ** DNA-Repair / Antimutagenic
• UT-unspecified: decreased mutagenicity of one smoker’s
urine (Rizzi et al., 1993)
• UT-CAEs: enhanced DNA repair (Sheng et al., 2001) ** External Use
• UT-POAs: Herpes simplex and Varicella-zoster (Immodal
1995, 1999a, 2002) ** HIV, adjunctive to antiretroviral therapy
• UT-POAs: stabilizes and/or reduces CD4-cell count,
increases vitality and mobility, reduced HIV-related symptoms
(Immodal, 1995, 1999a, 2002) ** Immune System Support
• UT-CAEs: extends immunity from pheumonia vaccine (Lamm
et al., 2001); increases white blood cells (Sheng et al.,
2001, 2000a) in animal study (Sheng et al, 2000b) ** Protection against UV radiation
• UT-unspecified: cytoprotective against UV radiation
in vitro (Sandoval et al., 2000; Rizzi et al., 1993). DOSAGES Crude Preparations
Note: There is little scientific or clinical documentation
supporting the use of crude cat’s claw products. Most
clinical research has been conducted on special standardized
preparations of various types. ** Uncaria guianensis
• Capsules: aqueous extract of bark powder, freeze-dried:
100 mg 1–3 times daily (Piscoya et al., 2001; Miller,
2001a). ** Uncaria tomentosa, chemotype and active component unspecified
• Capsules: 350–500mg, 1–2 times daily (CAMR,
1999).
• Decoction: 1 g root bark boiled for 15 minutes in
250 ml water, 1–3 times daily (Access, 2000; CAMR, 1999).
• Tincture: 1–2 ml, 2–3 times daily (CAMR,
1999). Standardized Preparations
** Uncaria tomentosa, standardized to CAEs
• Tablets: 350 mg daily (Lamm et al., 2001; Sheng et
al., 2001, 2000a). ** Uncaria tomentosa standardized to POAs
• Capsules: 20 mg (0.26 mg POAs), 3 times daily for
the first 10 days, and one capsule daily thereafter (Enzymatic
Therapy, 2002).
• Capsules: 1–3 caps/day (in acute cases, triple
dose for 1st wk) (Immodal, 1995).
• Drops: Adults: 3x20 d/day; 3–6 yrs: 3x7 d/day;
7–9 yrs: 3x10 d/day; 10–12 yrs: 3x15 d/day; 12+yrs:
3x20 d/day (Immodal, 1995).
• Tea: 20 g ground root bark in 1 L water, boil 45 min,
cool 10min, filter, add water to make 1 L. Adults: 60 ml decoction
in 60 ml hot water before breakfast; Children: decoction in
hot water before breakfast according to the following amounts:
3–6yrs: 20 ml in 20 ml; 7–9 yrs: 30 ml in 30 ml;
10–12 yrs: 50 ml in 50 ml; 12+yrs: same as adult (Immodal,
1995).
• Ointment: apply externally several times daily (Immodal,
1995).
• Spray: apply externally several times daily (Immodal,
1995). DURATION OF ADMINISTRATION At this time, there is little scientific information other
than ethnobotanical observations and 14 clinical trials (including
case reports and treatment observations on how long cat’s
claw can be consumed. Published clinical trials have been
conducted from as short as 4 weeks to 1 year of continuous
internal use, while unpublished treatment observations using
Krallendorn® (Immodal Pharmaka GmbH) products report on
continuous (uncontrolled) use for up to 10 years. There are
no known reports of adverse effects associated with the use
of cat’s claw preparations for extended periods. CHEMISTRY Although chemical research on cat’s claw began with
UG in 1952 (Cabieses, 1994), most of the chemical research
since then has focussed on UT and its alkaloids, particularly
the oxindole alkaloids. However, these alkaloids are a small
component of cat’s claw accounting for 9mg/g in Uncaria
tomentosa and 0.3mg/g in Uncaria guianensis (Sandoval et al.
2002),[what’s the general range in %? TK], which is
rich in flavanoids, quinovic glycosides, polyhodroxylated
triterpines, and tannins. While earlier studies reported alkaloids
as the active components of cat’s claw (Aguilar et al.,
2000; Laus et al., 1998; Stuppner et al., 1993; Kreutzkamp,
1984; Wagner et al., 1985a, 1985b), more recent studies report
that bioactivity is spread over a wide range of components
(Aguilar et al., 2002; Sandoval et al., 2002; Kitajima et
al., 2000; Lee et al., 1999; Sheng et al., 1998; Wirth and
Wagner, 1997; Aquino et al., 1991, 1989; Cerri et al., 1988),
and one study suggests that the anti-inflammatory and antioxidant
activities of cat’s claw are not affected by the presence
or relative level of alkaloids (Sandoval et al., 2002). As
in an determination of the source of bioactivity in an unknown
natural product any proposed active constituent must mimic
the actions of the extract from which it was derived, and
exert these actions at a concentration that reflects its relative
amount within that botanical or botanical extract. Uncaria guianensis
The little chemical research performed on UG has been limited
to its alkaloid, quinovic acid glycoside, and flavanol content.
UG contains very low levels of alkaloids — 35 times
less than UT (Sandoval et al., 2002; Miller et al., 2001)
— including speciophylline, mitraphylline, isomitraphylline,
uncarine E, and uncarine C (Sandoval et al., 2002; Miller
et al., 2001; Lee et al., 1999). UG also contains quinovic
acid glycosides (Yépez et al., 1991), flavanols (catechin,
epigallocatechin, epicatechin and epigallocatechin) (Sandoval
et al., 2002; Miller et al., 2001), and polyphenols (Miller
et al., 2001). UG has lower concentrations of the flavanols
(except for epigallocatechin) than does UT (Sandoval et al.,
2002). Uncaria tomentosa
UT has two chemotypes: the pentacyclic alkaloid type and tetracyclic
alkaloid type. The first contains pentacyclic oxindole alkaloids
(POAs), which some consider to be the main active component
of cat’s claw (Immodal 1995, 1999a, 1999b), with little
or no tetracyclic oxindole alkaloids (TOAs). The second chemotype
contains predominantly TOAs with either no POAs or up to a
considerable amount of POAs (Laus et al., 1997). TOAs are
considered antagonistic to the purported beneficial effects
of the POAs (Wurm et al., 1998) and thus the significance
in distinguishing the differences between the two chemotypes. POAs in UT include pteropodine, isopteropodine, speciophylline,
uncarine F, mitraphylline, isomitraphylline, uncarine E, and
uncarine C (Muhammad et al., 2001a; Laus et al., 1997; Stuppner
et al., 1992; Wagner et al., 1985b). The TOAs present in UT
include rhynchophylline, isorhynchophylline, corynoxeine,
isocorynoxeine (Keplinger et al., 1999; Laus et al., 1997;
Wagner et al., 1985b). Other alkaloids in UT include pentacyclic
indol alkaloids (akuammigine, tetrahydroalstonine, isoajmalicin)
(Laus et al., 1997), tetracyclic indol alkaloids (hirsutine,
dihydrocorynantheine, hirsuteine, corynantheine) (Keplinger
et al., 1999; Laus et al., 1997) and precursor alkaloids (5a-carboxystrictosidine,
lyaloside) (Aquino et al., 1991). In addition to alkaloids, UT contains triterpenes (ursolic
acid derivatives, quinovic acid glycosides, oleanolic acid
derivatives) (Laus et al., 1997; Aquino et al., 1991, 1990,
1989; Cerri et al.¸1988), polyhydroxylated triterpenes
(Aquino et al., 1991, 1990, 1989; Cerri et al.¸1988),
procyanidins ([-]-epicatechin, cinchonain 1a, cinchonain 1b)
(Wirth and Wagner, 1997), sterols (ß-sitosterol, stigmasterol,
campesterol) (Senatore et al., 1989), flavanols (catechin,
epigallocatechin, epicatechin and epigallocatechin) (Sandoval
et al., 2002), tannins (Laus et al., 1997; Aquino et al.,
1990, 1989) and carboxy alkyl esters (CAEs) (Sheng et al.,
2001). PHARMACOLOGICAL ACTIONS Human
** Uncaria guianensis
• Anti-inflammatory: significantly reduced pain associated
with activity in patients with osteoarthritis of the knee
(Piscoya et al., 2001). ** Uncaria tomentosa—unspecified preparations
• Antimutagenic: ingestion for 15 days decreased mutagenicity
of one smoker’s urine (Rizzi et al., 1993). ** Uncaria tomentosa—Standardized to CAEs
• Immunomodulation/immune support: enhanced response
to pneumoccoccal vaccine by reducing decay of antibody titers
and elevating lymphocyte/neutrophil) (Lamm et al., 2001);
decreased DNA damage (measured as single strand breaks in
DNA) from single dose of hydrogen peroxide and increased DNA
repair. (Sheng et al., 2001); increased white blood cell levels
in healthy males (Sheng et al., 2000a)
• Antimutagenic: decreased DNA damage (measured as single
strand breaks in DNA) from single dose of hydrogen peroxide
and increased DNA repair. (Sheng et al., 2001); enhances DNA
repair (Sheng et al., 2000a) ** Uncaria tomentosa—POA chemotype
• Anti-inflammatory: reduced number of painful and tender
joints and decreased duration of morning stiffness in rheumatoid
arthritis patients (Mur et al., 2002; Immodal, 1995, 2002);
eliminated symptoms and need for antacids in ulcer and gastritis
patients (Immodal 1995, 1999a).
• Immunomodulation/immune support: increased vitality
and reduced side effects in cancer patients undergoing chemotherapy,
radiation or surgery (Immodal 1995, 1999a, 2002); reduced
HIV-related symptoms and increased vitality of HIV patients
receiving antiretroviral treatment, increased lymphocyte numbers
in HIV patients although total leukocyte numbers remained
unchanged, stabilized or increased CD4 cell count in HIV patients
(Immodal 1995, 1999a, 2002). Animal
** Uncaria tomentosa—unspecified preparations
• Anti-inflammatory: significantly reduced paw volume
in carrageen-induced rat paw edema (Aguilar et al., 2002,
2000; Aquino et al., 1991); protected against NSAID-induced
gastritis by reducing lesions and apoptosis of the mucosal
epithelial cells (Sandoval et al., 2002); prevention of NSAID-induced
enteropathy in rats (Sandoval-Chacon et al, 1998) ** Uncaria tomentosa—Standardized to CAEs
• Immunomodulation/immune support: increased DNA repair
of single and double strand breaks from whole body irradiation
in rats (Sheng et al., 2000a); increased white blood cell
count sooner, and all fractions proportionally, compared with
control in rat model of chemotherapy-induced leukopenia (Sheng
et al, 2000b) ** Uncaria tomentosa–POA chemotype
• Anti-inflammatory: significantly reduced paw volume
in carrageen-induced rat paw edema (Aguilar et al., 2002,
2000) ** Isolated Components of Uncaria species
[Editors’ note: The studies referenced in this subsection
were performed with compounds isolated from U. rhynchophylla
or U. sinensis. While these compounds are also found in U.
guianensis and/or U. tomentosa, no studies have been performed
on extracts or fractions derived from UG or UT to verify that
these actions apply to them as well; thus their clinical significance
is undetermined. These studies have been included because
some proponents of the UT product standardized to POAs cite
them in support of the POA-antagonistic effects of TOAs.]
• Isorhynchophylline reduced blood pressure and heart
rate in rats and dogs (Shi et al., 1989); rhynchophylline
and isorhynchophylline reduced blood pressure and heart rate
in dogs, with isorhychophylline demonstrating a stronger effect
(Shi et al., 1992). In vitro
** Uncaria guianensis
• Anti-inflammatory: reduces excessive production of
cytokines and inflammatory mediators at the genetic level
(Sandoval et al., 2002; Piscoya et al., 2001; Sandoval et
al. 2000) with UG being more potent than UT (Sandoval et al.,
2002), and at extract concentrations far lower than required
for antioxidant activity (Piscoya et al., 2001); prevents
and eliminates gastrointestinal injury and inflammation in
NSAID-induced gastritis (Sandoval et al 2002).
• Antioxidant: scavenges DPPH (UG more potent than UT
despite lower concentrations of alkaloids and favanols), protects
against deoxyribose degradation in a dose-dependent manner,
and inhibits ABTS-radicals (Sandoval et al., 2002); effectively
scavenges free radicals and inhibits lipid peroxidation (Piscoya
et al., 2001); protects human gastric epithelial cells from
apoptosis induced by DPPH, peroxynitrite and H2O2 (Miller
et al., 2001). ** Uncaria tomentosa–unspecified preparations
• Anti-inflammatory: reduces excessive production of
cytokines and inflammatory mediators at the genetic level
with UG being more potent than UT, and at extract concentrations
far lower than required for antioxidant activity (Sandoval
et al., 2002; Piscoya et al., 2001); suppressed tumor necrosis
factor alpha (TNFa) production by 65–85% (Sandoval et
al., 2000); prevents and eliminates gastrointestinal injury
and inflammation in NSAID-induced gastritis (Piscoya et al.,
2001; Sandoval et al., 2000; Sandoval-Chacon et al., 1998).
Reduces COX2 expression (Piscoya et al, 2001)
• Antioxidant: scavenges DPPH (UG more potent than UT
reflected as lower IC50 value despite lower concentrations
of alkaloids and favanols), protects against deoxyribose degradation
in a dose-dependent manner, and inhibits ABTS-radicals (Sandoval
et al., 2002, 2000); effectively scavenges free radicals and
inhibits lipid peroxidation (Piscoya et al., 2001); protects
human gastric epithelial cells from apoptosis induced by DPPH,
peroxynitrite and hydrogen peroxide (Miller et al., 2001);
reduces peroxynitrite-induced apoptosis in human gastric epithelial
cells and in macrophages (Sandoval-Chacon et al., 1998); protective
against UV irradiation-induced cytotoxicity (Sandoval et al.,
2000).
• Immunomodulation/immune support: Increased cytokine
(IL-1 and IL-6) production in alveolar macrophages (Lemaire
et al., 1999) although high concentrations were used that
might reflect a toxicologic response and may be incompatible
with in vivo efficacy (Sandoval et al., 2002).
• Antimutagenic: protective against photomutagenesis,
(Rizzi et al., 1993). ** Uncaria tomentosa–Standardized to CAEs
• Immunomodulation/immune support: CAEs: significantly
increased PHA (phytohemagglutinin)-stimulated lymphocyte proliferation
in splenocytes and significantly elevated WBC count (Sheng
et al., 2000a).
• Antimutagenic: inhibited proliferation and induced
apoptosis in some tumor cell lines (Sheng et al., 1998) at
high concentrations that might not be achievable with standard
dosing and are likely to reflect a toxicologic response (Sandoval
et al., 2000). ** Uncaria tomentosa–POA chemotype
• Anti-inflammatory: moderate to weak activity against
cyclo-oxygenase-1 and -2 (COX-1 and COX-2) (Aguilar et al.,
2002);
• Antimutagenic: Inhibited proliferation in some human
tumor cell lines (Immodal, 1999b). ** Isolated Chemical Components from Cat’s Claw
• Immunomodulation/Immune Support: Phagocytosis was
enhanced in vitro by pteropodine, isomitraphylline & isorhynchophylline
(three POAs isolated from UT), but phagocytosis was enhanced
in vivo only after addition of catechin to POAs (Wagner et
al., 1985a, 1985b; Kreutzkamp, 1984); POAs isolated from UT
induced endothelial cells to release a factor that inhibited
proliferation of normal human lymphoblasts and stimulated
proliferation of normal human resting lymphocytes, while TOAs
dose-dependently reduced these effects (Wurm et al., 1998);
POAs isolated from UT inhibited growth of HL60 and U-937 leukemic
cells, with uncarine F demonstrating the strongest effect;
(Stuppner et al., 1993 cited in Keplinger et al., 1999); isopteropodine
(POA isolated from UT) increases the phagocytosis of granulocytes
and RES (reticuloendothelial system) cells (Kreutzkamp, 1984;
Wagner et al., 1985a, 1985b).
• Anti-inflammatory: 17 non-alkaloid HPLC fractions
from UT reduced TNFa and nitrite production induced by lipopolysaccharide
(LPS) in RAW 264.7 cells (Sandoval et al., 2002); one quinovic
acid glycoside isolated from UT demonstrated anti-inflammatory
effects, but it appears that the strong anti-inflammatory
effects of cat’s claw extracts and fractions may be
the result of the synergistic activity of a combination of
compounds (Aquino et al., 1991); moderate anti-inflammatory
activity has been demonstrated for ß-sitosterol, stigmasterol
and campesterol isolated from UT (Senatore et al., 1989);
one procyanidine (cinchonain Ib) isolated from UT inhibited
5-lipoxygenase, demonstrating anti-inflammatory activity (Wirth
and Wagner, 1997).
• Antiviral: 9 quinovic acid glycosides isolated from
UT showed moderate antiviral activity against vesicular stomatitis
virus, but at concentrations approaching cellular toxicity
(Aquino et al., 1989); two quinovic acid glycocides isolated
from UT (those with free carboxyl groups) reduced by 50% the
viral cytopathic effect of rhinovirus type 1b infection (Aquino
et al., 1989)
• Antimutagenic: Uncarine D showed weak cytocoxic activity
against SK-MEL, KB, BT-549 and SK-OV-3 cell lines with IC50
values between 30 and 40 ug/ml, while uncarine C exhibited
weak cytocoxicity only against ovarian carcinoma (IC50 at
37 ug/ml).(Muhammad et al., 2001b). However, given the concentration
of Uncarine C in cat’s claw, the amount of cat’s
claw that would have to be consumed to achieve these concentrations
in vivo is unrealistic. In addition to the antimutagenic activity,
UT extracts and factions exert a direct antiproliferative
activity on the MCF7 human breast cancer cell line. The bioassay-directed
fraction from barks and leaves resulted in the isolation of
2 active fractions, displaying an IC50 of 10 mg/ml and 20
mg/ml, respectively and an antiproliferative effect, with
about 90% of inhibition at a concentration of 100 mg/ml (Riva
et al., 2001). As noted above for the alkaloids Uncarine D
and C, these fractions would require an unrealistic consumption
of kilogram quantities of cat’ claw to achieve these
actions. ** Isolated Chemical Components from other Uncaria species
[Editors’ note: The studies referenced in this subsection
were performed with compounds isolated from U. rhynchophylla
or U. sinensis. While these compounds are also found in U.
guianensis and/or U. tomentosa, no studies have been performed
on extracts or fractions derived from UG or UT to verify that
these actions apply to them as well; thus their clinical significance
is undetermined. These studies have been included because
some proponents of the UT product standardized to POAs cite
them in support of the POA-antagonistic effects of TOAs.]
• Rhynchophylline and isorhynchophylline produced negative
chronotropic and inotropic effects (Zhu and Guozing, 1993);
rhynchophylline inhibits platelet aggregation (Chen et al.,
1992; Jin et al., 1991); rhynchophylline may be a calcium
antagonist (Sun et al., 1988; Zhang et al., 1987); rhynchophylline,
corynoxeine, isorhynchophylline, isocorynoxeine, and indole
alkaloids such as hirsuteine and hirsutine inhibit Ca2+ influx
which protects against glutamate-induced neuronal death (Shimada
et al, 1999; Yano et al., 1991); corynantheine and dihydrocorynantheine
have sedative action which in toxic dosages may lead to respiratory
paralysis and ataxia (Kanatani, 1985); corynantheine and dihydrocorynantheine
reduced specific [3H]5-HT binding and were found to be partial
agonists for 5-HT receptors (Kanatani, 1985)
MECHANISMS OF ACTION
Uncaria guianensis
** Anti-inflammatory
• Modifies gene expression by inhibiting redox-sensitive
transcription factors (Piscoya et al., 2001, Sandoval et al,
2002).
• Inhibits transcription factor NF-kB thereby modifying
expression of genes involved in the inflammatory process including
TNFalpha, inducible nitric oxide synthase (iNOS), and COX-2
(Sandoval et al., 2002; Piscoya et al., 2001).
• Inhibits production of TNFalpha (Sandoval et al.,
2002; Piscoya et al., 2001, Sandoval et al, 2000) with UG
being more potent than UT (Sandoval et al., 2002).
• Decreases production of lipopolysaccharide-induced
prostaglandin E-2 (Piscoya et al., 2001). ** Antioxidant
• Scavenges DPPH (UG more potent than UT despite lower
concentrations of alkaloids and flavanols), protects against
deoxyribose degradation in a dose-dependent manner, and inhibits
ABTS-radicals (Sandoval et al., 2002).
• Effectively scavenges free radicals and inhibits lipid
peroxidation (Piscoya et al., 2001; Miller et al., 2001).
• Protects human gastric epithelial cells from apoptosis
induced by DPPH, peroxynitrite and hydrogen peroxide (Miller
et al., 2001).
• Protects against UV radiation-induced cell death (Sandoval
et al, 2000)
• More effective in limiting the cellular response to
oxidants than degrading the oxidant itself (Miller et al.,
2001; Piscoya et al., 2001). Uncaria tomentosa–unspecified
** Anti-inflammatory
• Modifies gene expression by inhibiting redox-sensitive
transcription factors (Piscoya et al., 2001; Sandoval et al.,
2000; Sandoval-Chacon et al., 1998).
• Inhibits transcription factor NF-kB thereby modifying
expression of more than 28 genes involved in the inflammatory
process including TNFa, iNOS, and COX-2 (Aguilar et al., 2002;
Sandoval et al., 2002; Piscoya et al., 2001; Sandoval-Chacon
et al., 1998).
• Inhibits lipopolysaccharide-induced iNOS gene expression,
nitrite formation, and cell death (Sandoval-Chacon et al.,
1998).
• Inhibits production of TNFa, iNOS, and COX-2 (Sandoval
et al., 2002; Piscoya et al., 2001; Sandoval-Chacon et al.,
1998).
• Moderate to weak activity against COX-1 and COX-2
(Aguilar et al., 2002).
• Decreased production of lipopolysaccharide-induced
prostaglandin E-2 (Piscoya et al., 2001).
• Suppressed TNFa production (Sandoval et al., 2002;
Piscoya et al., 2001; Sandoval-Chacon et al., 1998) by 65–85%
(Sandoval et al., 2000). ** Antioxidant
• Scavenges DPPH (UG more potent than UT despite lower
concentrations of alkaloids and flavanols), protects against
deoxyribose degradation in a dose-dependent manner, and inhibits
ABTS-radicals (Sandoval et al., 2002; 2000).
• Effectively scavenges free radicals and inhibits lipid
peroxidation (Piscoya et al., 2001).
• Protects human gastric epithelial cells from apoptosis
induced by DPPH, peroxynitrite and H2O2 (Miller et al., 2001).
• Reduces peroxynitrite-induced apoptosis in human gastric
epithelial cells and in macrophages (Sandoval-Chacon et al.,
1998).
• Cytoprotective against UV irradiation (Sandoval et
al., 2000). ** Immunomodulation/immune support
• Increased cytokine (IL-1 and IL-6) production in alveolar
macrophages (Lemaire et al., 1999) although high concentrations
were used suggesting that this action could only be observed
in vivo with ingestion of kilogram quantities; a dosing regimen
that might reflect a toxicologic response (Sandoval et al.,
2002).
• Stimulates interleukin-1 (IL-1) and interleukin-6
(IL-6) production at a rate of 10.0 x and 7.5x control levels,
respectively. The effect is dose-dependent and diminishes
when the dose exceeds the range of 0.025-0.1 mg/mL (Lemaire
et al., 1999-in vitro). Uncaria tomentosa–Standardized to CAEs
** Anti-mutagenic
• Stimulation of DNA repair mechanisms (Sheng et al.,
2000a, 2001)
• Immunomodulation/immune support.
• Stimulates lymphocyte proliferation and elevates white
blood cells (Sheng et al., 2000a, 2000b; Lamm et al., 2000). ** Anti-tumor
• Suppresses tumor growth through selective induction
of apoptosis in two human leukemic cell lines (K562 and HL60)
and one human EBV-transformed B lymphoma cell line (Raji)
(Sheng et al., 1998); however, some authors have reported
apoptosis in these same cell lines due to inhibition of NF-kB
(Sandoval et al., 2002; Mannick et al., 1997; Beg and Baltimore,
1996). Uncaria tomentosa–POA chemotype
** Anti-inflammatory
• Moderate to weak activity against COX-1 and COX-2
(Aguilar et al., 2002).
• Inhibits synthesis of NF-kB (Aguilar et al., 2002;
2000). ** Immunomodulation/Immune Support
• POAs Induce the release of a lymphocyte-growth factor
from endothelial cells that regulates lymphocyte proliferation
(Wurm et al., 1998), but does not change total leukocyte numbers
(Keplinger et al., 1999). TOAs act antagonistically to this
effect of POAs (Wurm et al., 1998; Keplinger et al., 1999).
CONTRAINDICATIONS Cat’s claw has been contraindicated for leukemia patients
awaiting bone marrow transplant, any patient awaiting organ
transplant, persons with iatrically-induced immunosuppression
(e.g., organ transplants), autoimmune disease, multiple sclerosis,
or tuberculosis (CAMR, 1999). These contraindications are
based on the belief that cat’s claw is an immunostimulant.
However, some researchers disagree with this view (Miller,
2001b; Miller et al., 1999; Sandoval-Chacon et al., 1998;
Sandoval et al., 2000, 2002) and suggest that cat’s
claw may be helpful for transplant patients (Miller, 2001a).
The suppression of TNFalpha is a hallmark of numerous autoimmune
disorders, including those in which cat’s claw offers
benefits (arthritis, gut inflammation) and lowering TNFalpha
levels, as with cat’s claw, may indeed be desirable
rather than contraindicated for these patients. HIV/AIDS patients
should proceed with caution when introducing any new therapeutic
agent (Miller, 2001b). Cat’s claw is not for use in
children under 3 years due to lack of data regarding its effects
on the immature immune system (Immodal, 1995).
Pregnancy and Lactation: Not recommended (Jones, 1995) due
to lack of data regarding the effects of cat’s claw
on the immature immune system (Immodal, 1995). ADVERSE EFFECTS Recent human trials have concluded that the various cat’s
claw preparations tested are safe, with no adverse effects
reported in liver, renal, central nervous system, or hematological
function (Piscoya et al., 2001; Sheng et al., 2001, 2000a;
Lamm et al., 2000). Cat claw teas or crude extracts may cause
mild nausea, due to the bitter taste (Williams, 2001); however,
this appears speculative as nausea is not a frequently reported
effect. In one case report, a patient with systemic lupus
erythematosus experienced acute renal failure, which the authors
attributed to an idiosyncratic adverse reaction to the purported
cat’s claw preparation which was not adequately documented
(Hilepo et al., 1997). Uncaria guianensis
In one study infrequent reports of headache, dizziness, and
vomiting were reported but the incidence and frequency were
the same as with placebo (Piscoya et al., 2001). Uncaria tomentosa-CAEs
None reported. Uncaria tomentosa – POA chemotype
In AIDS patients and patients receiving large doses of chemotherapy,
individual cases of a mild erythrocytosis have been reported.
During the first 1–2 weeks of ingesting cat’s
claw tea (Krallendorn®) temporary constipation or mild
diarrhea was sometimes observed. Increased occurrence of acne
symptoms has been reported in HIV patients with prior symptoms.
In rare cases, elevated uric acid values were observed in
HIV and cancer patients; extensive die off in tumor patients
may cause lytic fever lasting 1–2 weeks (Immodal, 1999a,
1995). Components from Other Species of Uncaria
CC products containing larger amounts of TOAs could possibly
result in sedative effects and circulatory complaints (e.g.,
reduced blood pressure, coronary blood flow, and heart rate;
inhibited platelet aggregation) (Reinhard, 1999), due to the
reported effects of TOAs in Uncaria species other than UT
or UG (Shi et al., 1992, 1989; Jin et al., 1991). However,
no such effects have been reported in studies using products
made with UT or UG. DRUG INTERACTIONS Uncaria guianensis
None reported. Uncaria tomentosa – unspecified preparations
UT may potentially reduce the rate of metabolism and thus
increase serum levels of drugs taken orally as observed in
an in vitro assay on an unspecified UT tincture where the
CYP3A4 isozyme production was inhibited (Budzinski et al.,
2000). Some authors warn that some unspecified forms of cat’s
claw may increase the effects of anticoagulants and antihypertensives
(Fetrow and Avila, 2000; CAMR, 1999; Spaulding-Albright ,
1997; INPR, 1999). However, this is based on research on TOA
components isolated from Uncaria species other than UG or
UT. While it is possible that cat’s claw products rich
in TOAs may interact with these classes of drugs, there are
no reliable data to support this conclusion. Further, there
is little evidence to support this interaction with cat’s
claw products that contain little or no TOAs such as UG products
or the UT product Krallendorn®, or C-Med-100® (AF
Nutraceutical Group). Uncaria tomentosa – Standardized to CAEs
None reported. Uncaria tomentosa – POA chemotype
According to a communication to physicians and pharmacists
from the leading Austrian research and manufacturing company
on cat’s claw, the following advice should be given
to patients, based on the products proposed immunomodulatory
effects:
Take between chemotherapy treatments and after completion,
but not with chemotherapy treatments; Do not take in conjunction
with passive animal vaccines, intravenous hyperimmunoglobulin
therapy; intravenous thymic extracts, drugs using animal protein
or peptide hormones (e.g., bovine or porcine insulin), cryoprecipitates,
or fresh blood plasma (Immodal, 1995). AMERICAN HERBAL PRODUCTS ASSOCIATION (AHPA) SAFETY RATING Class 4: Insufficient data available for classification (McGuffin
et al., 1997).
[Editors’ Note: Cat’s claw was not widely marketed
during the time that the literature upon which this is based,
mainly 1980s and early to mid-1990s. Of potential relevance
is the fact that numerous studies show cat’s claw to
be safe. Human, animal, and in vitro studies demonstrate the
antimutagenic activity of cat’s claw (Sheng et al.,
2001, 2000a, 1998; Immodal, 1999b; Leon et al., 1996; Rizzi
et al., 1993), One human trial found no toxic effects at a
dose of 350 mg/day of C-Med-100® for 6 consecutive weeks
(Sheng et al., 2000a). One animal study reports an LD50 of
greater than 16 g/kg of body weight using a freeze-dried aqueous
extract of POA type UT (Kynoch and Lloyd, 1975), while a second
reports an LD50 of greater than 8 g/kg for C-Med-100. Another
study found daily oral administration of an aqueous-acid extract
of UT at 1000 mg/kg body weight for 28 days to be atoxic in
rats (Swendson and Skydsgaard, 1986). In an additional test,
an aqueous extract of UT was atoxic up to the maximum dosage
of 5g/kg body weight administered orally, and up to a concentration
of 2g/kg body weight administered intraperitoneally (Kreutzkamp,
1984). The alkaloid fraction of UT was found to be atoxic
up to the maximum dosage of 2 g/kg body weight orally and
1 g/kg body weight intraperitoneally (Kreutzkamp, 1984).] REGULATORY STATUS Austria: Prescription drug Krallendorn® (pentacyclic
chemotype).
Canada: Status undetermined. No products containing cat’s
claw are listed in the Health Canada Drugs Product Database
(Health Canada, 2001).
Germany: No German Commission E monograph (Blumenthal et al.,
1998). No monograph in the German Pharmacopoeia (DAB, 1999).
Sweden: No products containing cat’s claw are listed
in the Medical Products Agency (MPA) “Authorised Natural
Remedies” (MPA, 2001).
Switzerland: No products containing cat’s claw are listed
in the Swiss Drug Compendium (Morant and Ruppanner, 2001).
No monograph in the Swiss Pharmacopoeia.
U.K.: Not listed in the General Sale List (GSL, 1994). No
monograph in the British Pharmacopoeia.
U.S.: Dietary supplement (USC, 1994). No monograph in the
USP-NF. CLINICAL REVIEW There are 14 clinical trials on various preparations made
from the two species of Uncaria summarized in the clinical
studies Tables in this monograph. In general, the studies
are relatively small, most are uncontrolled, and some have
not been published. One prospective (P), randomized (R ),
double-blind (DB), placebo-controlled (PC), parallel group
(PG), multi-center (MC) trial was conducted on 45 men who
consumed 100 mg of a freeze-dried aqueous extract of UG for
4 weeks for osteoarthritis of the knee (Piscoya et al., 2001).
The study reports a significant improvement in pain associated
with activity, and medical and patient assessment scores,
but no significant improvement in pain at rest or at night,
or knee circumference. There were no significant side effects
in the UG and placebo groups. Three trials tested the UT-CAE preparation (C-Med-100®)
on immunomodulatory parameters. One small R, PC trial (n=23)
resulted in no loss of immunity after 5 months in patients
given a pneumonia vaccine after 2 months of treatment with
700 mg per day of the UT-CAE extract when compared to loss
in the placebo group (Lamm et al., 2001). Another small trial
(n=12) reported an increase in DNA repair with no adverse
effects (Sheng et al., 2001). An uncontrolled trial on healthy
volunteers resulted in an increase in white blood cells (Sheng
et al., 2000a). Three trials tested a proprietary extract of UT standardized
to POAs (Krallendorn®) for anti-inflammatory effects.
One 52-week trial on 40 people with rheumatoid arthritis (RA)
used 60 mg. per day of the extract in tablets (Mur et al.,
2002). The first phase (24 weeks) was R, DB, PC; the second
phase (28 weeks) was not blinded—all patients received
the treatment. There was a significant decrease in pain and
a shorter period of morning stiffness for the treatment group
compared to placebo after the first phase and a further reduction
after the second phase. The placebo-cat’s claw treatment
group experienced some reduction of symptoms in the second
phase. Two small uncontrolled, unpublished trials test the
UT-POA extract on patients with RA (Immodal, 1995, 2002) and
on ulcers and gastritis (Immodal, 1995, 1999a). Five trials tested the UT-POA extract for its effects on
immune function. All five trials are uncontrolled and unpublished,
thereby raising questions as to the significance of the results.
Two trials tested the UT-POA extract as an adjuvant therapy
for chemotherapy, radiation and brain tumor or surgery (Immodal
1995, 1999a, 2002) with generally favorable results, including
patients’ reports of a greater sense of vitality and
fewer side effects; three additional trials tested UT-POA
extract as an adjuvant therapy for HIV-positive patients (Immodal
1995, 1999a, 2002), with stabilized or increased CD-4 cell
counts, increased vitality and no adverse effects. Two uncontrolled, unpublished trials were performed on the
UT-POA extract in topical preparations for use on lesions
caused by Herpes simplex (Immodal, 1995, 1999a, 2002) and
Varicella zoster (Immodal, 1995, 1999a, 2002), showing improvement
and no adverse effects. BRANDED PRODUCTS C-MED-100®: AF Nutraceutical Group, Inc. / 31 Edgecliff
Road / Upper Montclair, NJ 07043 / U.S. / Tel.: (973) 267-6691/
Fax: (973) 267-6693 / Email: info@afnutra.com / www.afnutra.com.
Patented extract of Uncaria tomentosa, standardized to 8%
by Carboxy alkyl esters. Ultrafiltrated, 100% water soluble
extract spray-dried and compressed into 350 mg tablets. Krallendorn® Capsules: Immodal Pharmaka GmbH / Bundesstrasse
44 / 6111 Volders / Austria / Tel.: +43-05-22-45-7678 / Fax:
+43-05-22-45-7646. Cat’s claw root bark (pentacyclic
chemotype) hydroalcoholic extract standardized to contain
1.3% POAs, and undetectable TOAs. Krallendorn® Drops: Immodal Pharmaka GmbH. Cat’s
claw root bark (pentacyclic chemotype) hydroalcoholic extract
standardized to contain 1.3% POAs, and undetectable TOAs;
each 100 g of drop solution contains 600 mg cat’s claw
extract, water, ethanol (95% by volume). Krallendorn® Ointment: Immodal Pharmaka GmbH. Cat’s
claw root bark (pentacyclic chemotype) hydroalcoholic extract
standardized to contain 1.3% POAs, and undetectable TOAs;
each 75 g of ointment contains 300 mg cat’s claw extract. Krallendorn® Spray: Immodal Pharmaka GmbH. Cat’s
claw root bark (pentacyclic chemotype) hydroalcoholic extract
standardized to contain 1.3% POAs, and undetectable TOAs;
each 100 g of spray solution contains 600 mg cat’s claw
extract. Krallendorn® Tea: Immodal Pharmaka GmbH. Cat’s
claw root bark (pentacyclic chemotype), ground. Vincaria™: Rainforest Nutritionals, Inc, Carson City,
NV/ www.rainforest-inc.com/ a freeze dried extract of Uncaria
guianensis, 100mg capsules *American equivalents, if any, are found in the Product Table
on page XXX. REFERENCES Access. Professional Reference to Conditions, Herbs and Supplements.
Newton (MA): Integrative Medicine Communications; 2000.
Aguilar JL, Rojas PA, Capcha RC, Plaza A, Merfortl I. Anti-inflammatory
and molecular activity of extracts of Uña de gato with
different concentrations of pentacyclic and tetracyclic alkaloids
and of a freeze-dried extract. Congreso Internacional FITO
2000; Lima, Peru.
Aguilar JL, Rojas P, Marcelo A, Plaza A, Bauer R, Reininger
E, et al. Anti-inflammatory activity of two different extracts
of Uncaria tomentosa (Rubiaceae).
J Ethnopharmacol 2002;81(2):271–6.
Aquino R, DeFeo V, DeSimone F, et al. Plant metabolites. New
compounds and anti-inflammatory activity of Uncaria tomentosa.
J Nat Prod 1991;54(2):453–459.
Aquino R, DeSimone F, Vincieri FF, Pizza C, Gaes-Baitz E.
New polyhydroxylated triterpenes from Uncaria tomentosa. J
Nat Prod 1990 May-Jun:53(3):559–64.
Aquino R, DeSimone C, Pizza. Plant metabolites. Structure
and in vitro antiviral activity of quinovic acid glycosides
from Uncaria tomentosa and Guettarda platypoda. J Nat Prod
1989;52(4):679–685.
Beg AA, Baltimore D. An essential role for NF-kB in preventing
TNFa-induced cell death. Science 1996;274:782–410. Cited
in Sandoval M, Okuhama NN, Zhang X-J, Condezo LA, Lao J, Angeles
FM, Bobrowski P, Miller MSJ. Anti-inflammatory and antioxidant
activities of cat’s claw (Uncaria tomentosa and Uncaria
guianensis) are independent of their alkaloid content. Phytomed
2002;9(4):325–37.
Bianchi A, Keplinger U. Die Anwendung von Krallendorn—Kapseln
bei HIV-Infizierten-Auswertung einer offenen Studie mit 14
Patienten in den Klinischen Stadien CDC A2, B2 und C2 [presentation].
International AIDS-Kongress; Innsbruck, Austria; 1997. cited
in Immodal Pharmaka GmbH. Summary and assessment of: Clinical
examinations of Krallendorn® products (Radix Uncariae
tomentosae (WILLD.) DC mod. pent.). Volders, Austria: Immodal;
1999a. p. 20.
Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins
CW, Rister
RS, editors. Klein S, Rister RS (trans.). The Complete German
Commission E
Monographs?Therapeutic Guide to Herbal Medicines. Austin (TX):
American
Botanical Council; Boston: Integrative Medicine Communication;
1998.
Budzinski JW, Foster BC, Wandenhoek S, Arnason JT. An in vitro
evaluation of human cytochrome P450 3A4 inhibition by selected
commercial herbal extracts and tinctures. Phytomedicine 2000
Jul;7(4):273–82.
Cabieses F. The saga of the cat´s claw. Lima, Peru:
Via Lactea Editores; 1994.
CAMR. See: Center for Alternative Medicine Research.
Center for Alternative Medicine Research. Cat’s Claw
Summary [University of Texas, Health Science Center at Houston,
School of Public Health web site]. 4 May 1999. Available at:
http://www.sph.uth.tmc.edu/utcam/summary/cat.htm. Accessed
18 Oct 1999.
Cerri R, Aquino R, De Simone F, Pizza C. New quinovic acid
glycosides from Uncaria tomentosa. J Nat Prod 1988;51:257–61.
Cited in Sandoval M, Okuhama NN, Zhang X-J, Condezo LA, Lao
J, Angeles FM, Bobrowski P, Miller MSJ. Anti-inflammatory
and antioxidant activities of cat’s claw (Uncaria tomentosa
and Uncaria guianensis) are independent of their alkaloid
content. Phytomed 2002;9(4):325–37.
Chen CX, Jin RM, Li YK, Zhong J, Yue L, Chen SC, Zhou JY.
Inhibitory effect of rhynchophylline on platelet aggregation
and thrombosis. Acta Pharamacol Sin 1992;13(2):126-130.
DAB. See: Deutsches Arzneibuch.
Dean K. Water soluble extract for Uncaria: Method of preparation
and composition of a water soluble extract of the plant species
Uncaria [patent]. HerbalGram 2000;49:30.
Deutsches Arzneibuch (DAB). Stuttgart, Germany: Deutscher
Apotheker Verlag; 1999.
Enzymatic Therapy. Saventaro???www.enzy.com/products. 2001.
Ernst E. Possible interactions between synthetic and herbal
medicinal products. Part 1: a systematic review of the indirect
evidence. Perfusion 2000;13:4–15.
Fetrow CW, Avila JR. The Complete Guide to Herbal Medicines.
Springhouse(PA):Springhouse Corporation; 2000. p. 113–4.
General Sale List (GSL). Statutory Instrument 1994 No. 2410:
The Medicines (Products Other than Veterinary Drugs). London,
UK: Her Majesty’s Stationery Office (HMSO); 1994.
GSL. See: General Sale List.
Health Canada. Drug Product Database (DPD) Product Information.
Ottawa, Ontario: Health Canada Therapeutic Products Programme;
2001.
Hilepo J, Bellucci A, Mossey R. Acute renal failure caused
by cat’s claw herbal remedy in a patient with systemic
lupus erythematosus [letter]. Nephron 1997;77:361.
Immodal Pharmaka GmbH. Application in the treatment of brain
tumors. Krallendorn®-Medicaments: Special Information
for Physicians and Dispensing Chemists. 2nd revised ed. Austria:
Volders, Austria;1993b:16–17.
Immodal Pharmaka. Krallendorn® Uncaria tomentosa (Willd.)
DC Root Extract: Information for Physicians and Dispensing
Chemists. 3rd revised ed. Volders, Austria:Immodal;1995. Available
on request from immodal@volders.netwing.at.
Immodal Pharmaka. Radix Uncariae tomentosae (Willd.) DC.,
pentacyclic chemotype (Krallendorn®): summarized research.
Volders, Austria: Immodal; 2002.
Immodal Pharmaka. Summary and assessment of clinical examinations
of Krallendorn® products. Volders, Austria:Immodal;1999a.
Available on request from immodal@volders.netwing.at.
Immodal Pharmaka. Summary and assessment of: Pharmacodynamical
examinations of extracts of Uncaria tomentosa (Willd.) DC.
mod. pent. Volders, Austria: Immodal; 1999b.
Immodal Pharmaka GmbH. Therapy records over a 10-year-period.
Krallendorn®-Medicaments: Special Information for Physicians
and Dispensing Chemists. 2nd revised ed. Austria: Volders,
Austria;1993a:15–16.
INPR. See: Institute for Natural Products Research.
Institute for Natural Products Research (INPR). The NPDR Quick
Reference—Cat’s Claw [INPR web site]. 1999. Available
at http://www.naturalproducts.org/public/qr/catsclaw.html.
Accessed 4 Dec 2002.
Jin R, Chen C, Li Y, Xu, P. Effect of rhynchophylline on platelet
aggregation and experimental thrombosis. Acta Pharm Sinica
1991;26(4):246–249.
Jones K. Cat’s Claw Healing Vine of Peru. Seattle (WA):
Sylvan Press; 1995.
Kanatani H, Kohda H, Yamasaki K, et al. The active principles
of the branchlet and hook of Uncaria sinensis Oliv. examined
with a 5-hydroxytryptamine receptor binding assay. J Pharm
Pharmacol 1985;37:401–404.
Keplinger K, Laus G, Wurm M, et al. Uncaria tomentosa (Willd.)
DC-Ethnomedicinal use and new pharmacological, toxicological
and botanical results. J Ethnopharmacol 1999;64:23–34.
Kitajima M, Hashimoto K, Yokoya M, Takayama H, Aimi N, Sakai
LI. A new gluco indole alkaloid, 3, 4-dehydro-5-carboxystrictosidine,
from Peruvian Una de Gato (Uncaria tomentosa). Chem Pharm
Bull (Tokyo) 2000;48(10):1410–2.
Kreutzkamp B. Niedermolekulare Inhaltsstoffe mit immunstimulierenden
Eigenschaften aus Uncaria tomentosa, Okoubaka aubrevillei
und anderen Drogen [dissertation]. Munich, Germany: University
of Munich; 1984. Cited in Keplinger K, Laus G, Wurm M, et
al. Uncaria tomentosa (Willd.) DC-Ethnomedicinal use and new
pharmacological, toxicological and botanical results. J Ethnopharmacol
1999;64:23–34.
Kynoch and Lloyd, 1975 [TK: fill in full citation]. Cited
in Reinhard K. Uncaria tomentosa (Willd.) D.C. Cat’s
claw, una de gato, or saventaro. J Alternative Complement
Med 1999;5(2):143–51.
Lamm S, Sheng Y, Pero RW. Persistent response to pneumococcal
vaccine in individuals supplemented with a novel water soluble
extract of Uncaria tomentosa, C-Med-100®. Phytomedicine
2001;8(4):267–274.
Laus G, Brössner D, Keplinger K. Alkaloids of Peruvian
Uncaria tomentosa. Phytochemistry 1997;45(4):855–860.
Lee KK, Zhou BN, Lingston DG Vaisberg AJ, Hammond GB. Bioactive
indole alkaloids from the bark of Uncaria guianensis. Planta
Med 1999;65:759–60. Cited in Sandoval et al., 2002 Sandoval
M, Okuhama NN, Zhang X-J, Condezo LA, Lao J, Angeles FM, Bobrowski
P, Miller MSJ. Anti-inflammatory and antioxidant activities
of cat’s claw (Uncaria tomentosa and Uncaria guianensis)
are independent of their alkaloid content. Phytomed 2002;9(4):325–37.
Lemaire I, Assinewe V, Cano P, Awang D, Arnason J. Stimulation
of interleukin-1 and –6 production in alveolar macrophages
by the neotropical liana, Uncaria tomentosa (Uña de
Gato). J Ethnopharmacol 1999;64:109–115.
Leon FR, Ortiz N, Antunez de Mayolo A, Namisato T, Monge R.
Antimutagnic activity of a freeze-dried aqueous extract of
Uncaria tomentosa in smokers and non-smokers. Third European
Colloquium on Ethnopharmacology, Genova, Italy 1996:255. Cited
in Reinhard K. Uncaria tomentosa (Willd.) D.C. Cat’s
claw, una de gato, or saventaro. J Alternative Complement
Med 1999;5(2):143–51.
Anon. Cat’s Claw. The Lawrence Review of Natural Products
1996;Apr:1–3.
Mannick EE, Mishra J, Marque J, Clavell M, Miller MJS, Oliver
PD. Inhibitors of nuclear factor Kappa B cause apoptosis in
cultured macrophages. Mediators Inflammation 1997;6:225–32.
Cited in Sandoval et al., 2002 Sandoval M, Okuhama NN, Zhang
X-J, Condezo LA, Lao J, Angeles FM, Bobrowski P, Miller MSJ.
Anti-inflammatory and antioxidant activities of cat’s
claw (Uncaria tomentosa and Uncaria guianensis) are independent
of their alkaloid content. Phytomed 2002;9(4):325–37.
McGuffin M, Kartesz JT, Leung AY, Tucker AO. The American
Herbal Product Association’s Herbs of Commerce, 2nd
ed. Silver Spring (MD): American Herbal Products Association;
2000.
McGuffin M, Hobbs C, Upton R, Goldberg A. American Herbal
Products Association’s Botanical Safety Handbook: Guidelines
for the Safe Use and Labeling for Herbs of Commerce. Boca
Raton (FL): CRC Press; 1997.
Medical Products Agency (MPA). Naturläkemedel: Authorised
Natural Remedies (as of January 24, 2001). Uppsala, Sweden:
Medical Products Agency; 2001.
Miller M. Personal communication to M. Blumenthal. Jun 4,
2001a.
Miller MJS. Alternative focus: Amazonian medicinals for gastrointestinal
health. HIV Resource Review 2001;5:1–6.
Miller MJS, Angeles FM, Reuter BK, Bobrowski P, Sandoval M.
Dietary antioxidants protect gut epithelial cells from oxidant-induced
apoptosis. BMC Complement Altern Med 2001b;1:11.
Miller MJS, Zhang XJ, Charbonnet RM, Clark DA, Sandoval M.
The anti-inflammatory actions of the herbal medicine, cat's
claw, are due to a suppression of NF-kB activation and inhibition
of gene expression. Pediatric Res 1999;45:114A (abstract).DELETE
replace with Sandoval et al 2000 in text Cited in Piscoya
J, Rodriguez Z, Bustamante SA, Okuhama NN, Miller MJS, Sandoval
M. Efficacy and safety of freeze-dried cat’s claw in
osteoarthritis of the knee: mechanisms of action of the species
Uncaria guianensis. Inflamm Res 2001;50:442–8.
Morant J, Ruppanner H (eds.). Arzneimittel-Kompendium der
Schweiz® 2001. Basel, Switzerland: Documed AG; 2001.
MPA. See: Medical Products Agency.
Muhammad I, Khan IA, Fischer NH, Fronczek FR. Two stereoisomeric
pentacyclic oxindole alkaloids from Uncaria tomentosa: uncarine
C and uncarine E. Acta Cryst 2001a;C57:240–2.
Muhammad I, Dunbar DC, Khan RA, Ganzera M, Khan IA. Investigation
of Una de Gato. 7-deoxyloganic acid and 15N NMR spectroscopic
studies on pentacyclic oxindole alkaloids from Uncaria tomentosa.
Phytochemistry 2001b;57(5):781–5.
Mur E, Hartig F, Eibl G, Schirmer M. Randomized double blind
trial of an extract from the pentacyclic alkaloid-chemotype
of Uncaria tomentosa for the treatment of rheumatoid arthritis.
J Rheumatol 2002;29:678–81.
Obregon VL. Cat’s Claw. Genus Uncaria. Botanical, Chemical
and Pharmacological Studies of Uncaria tomentosa (Willd.)
DC and Uncaria guianensis (Aubl.). 1995; Lima, Peru: Institute
of American Phytotherapy. (English translation of work published
in Spanish in 1994).
Pero RW, inventor; CampaMed, Inc., assignee. Method of preparation
and composition of a water soluble extract of the plant species
Uncaria. US patent 6,039,949. 2000 Mar 21.
Piscoya J, Rodriguez Z, Bustamante SA, Okuhama NN, Miller
MJS, Sandoval M. Efficacy and safety of freeze-dried cat’s
claw in osteoarthritis of the knee: mechanisms of action of
the species Uncaria guianensis. Inflamm Res 2001;50:442–8.
Reinhard K. Uncaria tomentosa (Willd.) D.C. Cat’s claw,
una de gato, or saventaro. J Alternative Complement Med 1999;5(2):143–151.
Richman A, Witkowski JP. Annual herb sales survey. Whole Foods
2001 Oct:23–30.
Riva L, Coradini D, Di Fronzo G, De Feo V, De Tommasi N, De
Simone F, Pizza C. The antiproliferative effects of Uncaria
tomentosa extracts and fractions on the growth of breast cancer
cell line. Anticancer Res 2001;21(4A):2457–61.
Rizzi R, Re F, Bianchi A, De Feo V, de Simone F, Bianchi L,
Stivala L. Mutagenic and antimutagenic activities of Uncaria
tomentosa and its extracts. J Ethnopharmacol 1993;38:63–77
.
Sandoval M, Charbonnet R, Okuhama N, Roberts J, Krenova Z,
Trentacosti A, Miller M. Cat's claw inhibits TNFalpha production
and scavenges free radicals: role in cytoprotection. Free
Radic Biol Med 2000;29(1):71–78.
Sandoval M, Okuhama NN, Zhang X-J, Condezo LA, Lao J, Angeles
FM, Bobrowski P, Miller MJS. Antiinflammatory and antioxidant
activities of cat’s claw (Uncaria tomentosa and Uncaria
guianensis) are independent of their alkaloid content. Phytomedicine
2002;9(4):325–37.
Sandoval-Chacon M, Thompson JH, Lui X, Mannick E, Sadowska-Krowicka
H, Charbonnet R, Clark D, Miller M. Anti-inflammatory actions
of Cat’s claw: the role of NF-kappaB. Aliment Pharmacol
Ther 1998;12:1279–1289.
Santa Maria A, Lopez A, Diaz M, et al. Evaluation of the toxicity
of Uncaria tomentosa by bioassays in vitro. J Ethnopharmacol
1997;57:183–191.
Senatore et al. Phytochemical and biological study of Uncaria
tomentosa. Bulletin de la Societe Italie Speriment 1989;65:517–520.
Sheng Y, Pero R, Amiri A et al. Induction of apoptosis and
inhibition of proliferation in human tumor cells treated with
extracts of Uncaria tomentosa. Anticancer Res 1998;18:3363–3368.
Sheng Y, Li L, Holmgren C, Pero RW. DNA repair enhancement
of aqueous extracts of Uncaria tomentosa in a human volunteer
study. Phytomedicine 2001;8(4) 275–282.
Sheng Y, Bryngelsson C, Pero R. Enhanced DNA repair, immune
function and reduced toxicity of C-Med-100®, a novel aqueous
extract from Uncaria tomentosa. J Ethnopharmacol 2000a;69:115–126.
Sheng Y, Pero R, Wagner H. Treatment of chemotherapy-induced
leukopenia in the rat model with aqueous extract from Uncaria
tomentosa. Phytomedicine 2000b;7(2):137–143.
Shi JS, Huang B, Wu Q, Ren RX, Xie XL. Effects of rhynchophylline
on motor activity of mice and serotonin and dopamine in rat
brain. Acta Pharm Sinico 1992; 14(2):114–7.
Shi JS, Liu GX, Wu Q, Zhang W, Huang XN. Hypotensive and hemodynamic
effects of isorhynchophylline in conscious rats and anesthetized
dogs. Chin J Pharmacol Toxicol. 1989;3(3):205-210.
Shimada Y, Goto H, Itoh T, Sakakibara I, Kubo M, Sasaki H,
Terasawa K. Evaluation of the protective effects of alkaloids
isolated from the hooks and stems of Uncaria sinensis on glutamate-induced
neuronal death in cultured cerebellar granule cells from rats.
J Pharm Pharmacol 1999;51(6):715-722.
Spaulding-Albright N. A review of some herbal and related
products commonly used in cancer patients. J Am Diet Assoc.
1997;97:S208-215.
Stuppner H, Sturm S, Geisen G, Zillian U, Konwalinka G. A
differential sensitivity of oxindole alkaloids to normal and
leukemic cell lines. Planta Medica. 1993;59:Supplement,A583.
Stuppner H, Sturm S, Konwalinka G. HPLC analysis of the main
oxindole alkaloids of Uncaria tomentosa. Chromatographia 1992;34:597–600.
Sun A-S, Liu G-X, Wang X-Y, Zhang W, Luang X-N. Effects of
rhynchophylline on contraction of isolated rat uterus. [in
Chinese]. Ch J Pharm Tox 1988;2(2):93–97.
Swendson and Skydsgaard, 1986 [TK: fill in full citation].
Cited in
United States Congress (USC). Public Law 103–417: Dietary
Supplement Health and Education Act of 1994. Washington, DC:
103rd Congress of the United States; 1994.
Unterberger H. Fallbeobachtungen bei Ulcera und Gastritiden
[unpublished]. Interne Ordnungsnummer: IntNo 111/83, 112/83,
129/84, 255/84, 256/84, 257/84, 265/84. cited in Immodal Pharmaka
GmbH. Krallendorn® Uncaria tomentosa (WILLD.) DC root
extract: Information for physicians and dispensing chemists,
3rd revised ed. Volders, Austria: Immodal; 1995.
USC. See: United States Congress.
Wagner H, Proksch A, Vollmar A, Kreutzkamp B, Bauer J. In
vitro phagocytosis stimulation by isolated plant materials
in a chemoluminescence-phagocytosis model [in German]. Planta
Med 1985a Apr;(2):139–44.
Wagner H, Kreutzkamp B, Jurcic K. The alkaloids of Uncaria
tomentosa and their phagocytosis-stimulating action [in German].
Planta Med 1985b Oct;(5):419-23.
Wang X , Zhang L, Hua Z. Blocking effect of rhynchophylline
on calcium channels in isolated rat ventricular myocytes.
Chung Kuo Yao Li Hsueh Pao 1994;15(2):115–118.
Williams JE. Review of antiviral and immunomodulating properties
of plants of the Peruvian rainforest with a particular emphasis
on Uña de gato and Sangre de grado. Altern Med Rev
2001 Dec;6(6):567-79.
Wirth C, Wagner H. Pharmacologically active procyanidines
from the bark of Uncaria tomentosa. Phytomedicine 1997;4(3):265–266.
Wurm M, Kacani L, Laus G, Keplinger K, Dierich M. Pentacyclic
oxindole alkaloids from Uncaria tomentosa induce human endothelial
cells to release a lymphocyte-proliferation-regulating factor.
Planta Med 1998;64:701–704.
Yano S, Horiuchi H, Horie S, Aimi N, Sakai S, Watanabe K.
Ca2+ channel blocking effects of hirsutine, an indole alkaloid
from Uncaria genus, in the isolated rat aorta. Planta Med
1991;57:403-405.
Yepez AM, de Ugaz OL, Alvarez CM, De Feo V, Aquino R, De Simone
F, et al. Quinovic acid glycosides from Uncaria guianensis.
Phytochemistry 1991;30(5):1635–7.
Zechberger J. Studie über die Verabreichung von Krallendorn®—Tropfen
bei Hirntumoren [unpublished]. Innsbruck, Austria: University
Hospital of Innsbruck; 1992. cited in Immodal Pharmaka GmbH.
Summary and assessment of: Clinical examinations of Krallendorn®
products (Radix Uncariae tomentosae (WILLD.) DC mod. pent.).
Volders, Austria: Immodal; 1999a. p. 20.
Zhang W, Liu GX, Huang XN. Effect of rhynchophylline on contraction
of rabbit aorta. Acta Pharmacol Sin 1987;8(5):425-429.
Zhu Y, Guoxing HX. Negative chronotropic and inotropic effects
of rhynchophylline and isorhynchophylline on isolated guinea
pig arteria. Chin J Pharmacol Toxicol 1993;7(2):117-121.
### New Glossary Words and Abbreviations
TNF?: tumor necrosis factor alpha
COX-2:
NF-kB:
iNOS:
IL-1
IL-6
TOA
POA
CAE
UT
UG
DPPH
ABTS
|
